We observed that Mito‐ATO significantly increased tumor infiltrating CD4+ T cells (Figure 2B), and also resulted in a significant reduction of G‐MDSCs and Foxp3+ Tregs within tumors receiving Mito‐ATO treatment (Figure 2C,D). This evidence concerns the gene CD4 and neoplasm.